NCT06691321Recruiting
Caspofungin for Pneumocystis Pneumonia in PLWHIV.
Efficacy of Caspofungin for Pneumocystis Jirovecii Pneumonia in People Living With HIV/AIDS.
Source: ClinicalTrials.gov · Last updated 19 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Pneumocystis jirovecii pneumonia is a significant concern in peaple with HIV/AIDS, often severe and potentially fatal. While trimethoprim/sulfamethoxazole remains the primary treatment, safety concerns exist with alternative options. Research on Pneumocystis jirovecii's beta-D glucan composition has prompted investigations into echinocandins like caspofungin, showing promise in murine models and some positive results in human studies. Evaluating caspofungin's efficacy through observational studies is crucial due to safety advantages over current treatments and limited documented data.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 11 Nov 2024
- Start date
- 1 Aug 2023
- Primary completion date
- 1 Jan 2025
- Lead sponsor
- Instituto Nacional de Enfermedades Respiratorias
- Diseases
- HIV
- NCT number
- NCT06691321
What you commit to
- Study type: Observational
- Planned participants: 60
- From 1 Aug 2023 to the primary completion date, 1 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients who have developed an additional opportunistic lung infection during their hospitalization, other than cytomegalovirus pneumonitis or SARS-CoV-2 pneumonia.
Other
- With a treatment switch to caspofungin after day 7 of treatment initiation (applies only to group B).
Who the study is looking for
- Diagnosis of probable or proven PCP, according to its diagnostic classification (refer to classification at the end of this section).
- Have clinical laboratory and virological diagnostic laboratory studies at the time of admission.
- Classification criteria for Pneumonia by P. jirovecii according to Robert-Gangneux et al.:
- Proven: Confirmation by pathology or microbiology. Possible: Presence of three out of four clinical or radiological criteria. Probable: Presence of one clinical or radiological criterion without another identified microorganism.
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Center for Research in Infectious Diseases (CIENI) Coordinator of this site? Confirm its status | Mexico City | Mexico | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.